

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 018002-001010US

Assistant Commissioner for Patents  
Box PCT  
Washington, D.C. 20231

Rec'd PCT/PTO 22 MAY 2001

#71  
a

On May 21, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Helen J. Bruegel

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schneider *et al.*

Application No.: 09/485,193

Filed: February 3, 2000

For: USE OF PROTHYMOSIN IN THE  
DIAGNOSIS AND TREATMENT OF  
ENDOMETRIOSIS

Examiner: Not Assigned

Art Unit: 1623

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed April 30, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 3, at the end of the application.

004227 ESTS460